US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
ImmunityBio Inc (IBRX)
ImmunityBio Inc (IBRX) ニュース

IBRX

ImmunityBio (IBRX)

ImmunityBio Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IBRX

1 2 3 4 5 6 7 8 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/03/03	21 : 47	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:IBRX	ImmunityBio Inc
2025/03/03	21 : 42	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IBRX	ImmunityBio Inc
2025/03/03	21 : 30	Business Wire	ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024	NASDAQ:IBRX	ImmunityBio Inc
2025/02/28	09 : 10	Business Wire	ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer	NASDAQ:IBRX	ImmunityBio Inc
2025/02/26	11 : 11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2025/02/26	11 : 11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2025/02/26	11 : 11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2025/02/19	23 : 00	Business Wire	FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage	NASDAQ:IBRX	ImmunityBio Inc
2025/02/14	05 : 05	Business Wire	ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ	NASDAQ:IBRX	ImmunityBio Inc
2025/02/13	10 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2025/02/08	06 : 52	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IBRX	ImmunityBio Inc
2025/01/29	22 : 30	Business Wire	ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer	NASDAQ:IBRX	ImmunityBio Inc
2025/01/27	23 : 00	Business Wire	ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ	NASDAQ:IBRX	ImmunityBio Inc
2025/01/25	10 : 47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2025/01/16	07 : 20	Business Wire	ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency	NASDAQ:IBRX	ImmunityBio Inc
2025/01/16	07 : 20	Business Wire	ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom	NASDAQ:IBRX	ImmunityBio Inc
2025/01/06	23 : 00	Business Wire	ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective	NASDAQ:IBRX	ImmunityBio Inc
2025/01/04	06 : 54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/12/12	22 : 00	GlobeNewswire Inc.	D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering	NASDAQ:IBRX	ImmunityBio Inc
2024/12/12	20 : 45	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IBRX	ImmunityBio Inc
2024/12/11	21 : 46	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IBRX	ImmunityBio Inc
2024/12/11	21 : 30	Business Wire	ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock	NASDAQ:IBRX	ImmunityBio Inc
2024/12/11	07 : 28	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IBRX	ImmunityBio Inc
2024/12/11	07 : 13	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IBRX	ImmunityBio Inc
2024/12/11	06 : 24	Business Wire	ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock	NASDAQ:IBRX	ImmunityBio Inc
2024/11/22	00 : 00	PR Newswire (US)	ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment	NASDAQ:IBRX	ImmunityBio Inc
2024/11/19	23 : 00	PR Newswire (US)	ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements	NASDAQ:IBRX	ImmunityBio Inc
2024/11/19	22 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IBRX	ImmunityBio Inc
2024/11/19	22 : 00	Business Wire	ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months	NASDAQ:IBRX	ImmunityBio Inc
2024/11/12	21 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IBRX	ImmunityBio Inc

Showing the most relevant articles for your search:NASDAQ:IBRX

1 2 3 4 5 6 7 8 次へ >>

Alpha Metallurgical Reso...

Wyndham Destinations

Zacks Small Mid Cap ETF

Republic of Philippines

Caisse Depots Et Consign...

Chain Bridge Bancorp

The Revel Collective

Eib Tf 9,25% Ge27 Brl

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約